It was found, however, conversely, that patients with NSCLC harboring EGFR mutations had significantly higher metabolic activity of 18F-FDG (e.g., SUVmax) as compared to patients with wild-type EGFR [40, 41]. Here, EGFR is linked to non-small cell lung carcinoma.